The role of the Prostate Cancer Subcommittee Professor Lisa Horvath is the chair of the ANZUP Prostate Cancer subcommittee and Professor Jarad Martin is the deputy chair. They lead the subcommittee and provide oversight of trials within the Prostate Cancer trials portfolio, as well as development of new trial concepts. The Prostate Cancer Subcommittee is made up of over 500 members of different disciplines from around Australia and New Zealand.
Meet the Professors! Professor Lisa Horvath Professor Lisa Horvath is the Director, Department of Medical Oncology, and inaugural Director of Research at the Chris O’Brien Lifehouse. She is also the Professor of Medical Oncology (Genitourinary cancer) at the University of Sydney and Head of Advanced Prostate Cancer Research at the Garvan Institute for Medical Research. She has an active clinical practice and is involved with a large number of clinical trials in prostate and colorectal cancers in addition to phase I trial work. Having completed medical school at the University of Sydney and trained in medical oncology at Royal Prince Alfred Hospital, she subsequently worked at the Garvan Institute completing her PhD in translational research in 2004. She has authored over 100 original research papers published in peerreviewed journals in the last 20 years across the fields of cancer biology, biomarkers and clinical trials. Prof Horvath has been involved in numerous ANZUP clinical trials over the last 10 years as well as an author on the ENZAMET study. She is a board director for ANZUP, and a member of the ANZUP Scientific Advisory Committee.
26 A LITTLE BELOW THE BELT
Professor Jarad Martin Professor Jarad Martin is a Radiation Oncologist and departmental Director of Research working at the Calvary Mater Newcastle. He completed his fellowship in 2005 and undertook a genitourinary oncology clinical research fellowship at the Princess Margaret Hospital in Toronto, winning the academic excellence in research award from that institution. His primary clinical and research interests are in urologic and gastrointestinal cancers, including the application of stereotactic radiotherapy for genitourinary tumours. In 2006 he accepted a position in Regional Queensland in Toowoomba and established the Toowoomba Cancer Research Centre (TCRC). Prof Martin assumed the Australasian Primary Investigator role for the successful PROFIT clinical trial randomising men with prostate cancer to receive either a standard 8 week course or an experimental 4 weeks’ regimen of radiotherapy. He relocated to Newcastle in 2012 and continued to develop a number of senior roles in national bodies. He was the Clinical Liaison for Trans-Tasman Radiation Oncology Group (TROG) from 2012-2015 and was the chair of the Faculty of Radiation Oncology Research Committee from 2011-2015. He has been on the executive committee of the Faculty of Radiation Oncology Genitourinary Group (FROGG) as well as the Scientific Advisory Committee of ANZUP. Prof Martin has several currently accruing multicentre prospective clinical trials, over 70 peer reviewed publications, and has also recently completed a PhD.
